Based upon its experience in the marketplace, Sheppard Mullin expects that private equity firms investing and operating in the healthcare space will encounter more antitrust scrutiny not just of roll-ups that combine physician groups or facilities operating in the same line of business into larger organizations, but also deals that combine payors, physicians, facilities, healthcare tech platforms, and other healthcare companies. In anticipation of such scrutiny from the Agencies, private equity firms should keep in mind the following three key takeaways as they navigate an increasingly challenging antitrust enforcement landscape.
Read the full article: Vertical Deals in Healthcare: Key Antitrust Takeaways for Private Equity Firms //
Source: https://www.lexology.com/library/detail.aspx?g=3a70311a-d7e4-4543-8d09-99497aba25fc